COMMUNIQUÉS West-GlobeNewswire

GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
10/12/2025
Study met its primary endpoint demonstrating that GRI-0621 was well tolerated over 12 weeks of treatment, with no drug-related severe or serious adverse events and no increase in GI issues when used with existing [...]
Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome
10/12/2025
Multiple active sites and strong US enrollment continue to support Q3 2026 timing for topline data readout Clinical trial sites in Canada and the United Kingdom have received regulatory clearance to enroll All patients [...]
BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium (SABCS)
10/12/2025
Preclinical data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα, strongly inhibits pAKT signaling in tumor cells without inducing hyperglycemia, and shows robust anti-tumor activity both as monotherapy [...]
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
10/12/2025
BOSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine [...]
Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025
10/12/2025
Company will host conference call and live webcast to review and discuss the data at 8:00 am ET NORWOOD, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical stage [...]
MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach
10/12/2025
CHICAGO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology (NYSE American: MAIA) – The treatment paradigm for advanced non-small cell lung cancer (NSCLC) is undergoing another shift. After a decade of targeted [...]
Carrick Therapeutics Announces Positive Results from Phase 2 Randomized Trial of Samuraciclib in Combination with Fulvestrant in Patients with Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer
10/12/2025
Overall response rate (ORR) of 55% and median progression-free survival of 14.5 months in patients without TP53 gene mutation Phase 2 results presented at 2025 San Antonio Breast Cancer Symposium BOSTON, Dec. 10, 2025 ( [...]
Tiny Health Celebrates 100,000 Tests Milestone, Expands from Baby Gut Health Pioneer to Longevity Innovator
10/12/2025
The microbiome startup powering preventive and personalized health launches new aging study and deepens partnerships with leading wellness and longevity programs AUSTIN, Texas, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Tiny [...]
Persephone Biosciences Announces Publication in Cell Host & Microbe Highlighting the Critical Need to Restore Bifidobacterium in the Infant Gut Microbiome
10/12/2025
- Evidence shows infant microbiome trajectories established in the first months of life persist, shaping immune function and allergy risk into childhood - - Targeted early-life probiotic interventions using B. infantis [...]
EssilorLuxottica joins forces with Fondazione Chips-IT to accelerate the future of smart eyewear
10/12/2025
EssilorLuxottica joins forces with Fondazione Chips-IT to accelerate the future of smart eyewear Paris, France (10 December 2025) – EssilorLuxottica announces it is joining forces with Fondazione Chips-IT, Italy’s [...]
EssilorLuxottica va collaborer avec la fondation Chips-IT pour accélérer dans les lunettes connectées
10/12/2025
EssilorLuxottica va collaborer avec la fondation Chips-IT pour accélérer dans les lunettes connectées Paris, France (10 décembre 2025) – EssilorLuxottica a annoncé aujourd'hui une collaboration avec la fondation Chips- [...]
GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy
10/12/2025
Highly encouraging early data from the ongoing Phase 1b study evaluating investigational drug GNS561 with a MEK inhibitor (MEKi) in KRAS mutated cholangiocarcinoma (CCA), positioning this novel combination as a [...]
GENFIT : GNS561 montre une activité antitumorale prometteuse en combinaison thérapeutique
10/12/2025
Données préliminaires très encourageantes de l’étude de Phase 1b en cours évaluant le médicament expérimental GNS561 associé à un inhibiteur de MEK (MEKi) dans le cholangiocarcinome (CCA) avec mutation KRAS, [...]
Tristan Imbert co-opted as Independent Director
10/12/2025
Press Release Paris – December 10, 2025 - EUROAPI today announces that, following the resignation of Rodolfo Savitzky from his position as Independent Director (effective December 31, 2025) 1 , and upon the [...]
Tristan Imbert coopté Administrateur Indépendant
10/12/2025
Communiqué de presse Paris - Le 10 décembre 2025 - EUROAPI annonce aujourd’hui qu’à la suite de la démission de Rodolfo Savitzky de son poste d’Administrateur Indépendant (effective au 31 décembre 2025) 1 et sur [...]
Bioxodes raises €5.5 million Series A extension to continue preparations for pivotal trial of breakthrough stroke candidate
10/12/2025
Newton Biocapital enters as new investor, strong participation of existing investors Pivotal Phase 2b trial initiation in 2027 of BIOX-101 to treat intracerebral hemorrhage BIOX-101 may be commercialized as early as H2 [...]
Bioxodes lève 5,5 millions d'euros dans le cadre d'une extension de la Série A afin de poursuivre la préparation d’un essai pivot pour son candidat-médicament innovant dans le traitement de l'AVC
10/12/2025
Newton Biocapital entre au capital en tant que nouvel investisseur, importante participation des investisseurs historiques Lancement en 2027 d’un essai pivot de phase 2b portant sur BIOX-101 dans le traitement de l’AVC [...]
Oxford BioTherapeutics Enters into a Strategic Collaboration with GSK to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer
10/12/2025
Collaboration leverages OBT's proprietary OGAP®-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology targets The agreement - OBT's second high-profile pharma collaboration [...]
New Hypertension publication underscores aprocitentan’s potential in managing hypertension patients with CKD
10/12/2025
New analysis from landmark Phase 3 PRECISION trial published in Hypertension highlights the renal-protective benefits of aprocitentan in addition to the marked reduction in blood pressure in a high-risk CKD population [...]

Pages